Skip to main content
Erschienen in: Annals of Nuclear Medicine 2/2015

01.02.2015 | Original Article

Investigation of 11C-PiB equivocal PET findings

verfasst von: Chisa Hosokawa, Kazunari Ishii, Tomoko Hyodo, Kenta Sakaguchi, Kimio Usami, Kenji Shimamoto, Yuzuru Yamazoe, Makoto Hosono, Kazushi Hanada, Masami Ueda, Kazuma Saigo, Takamichi Murakami

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

We have encountered occasional equivocal findings when assessing cerebral cortical amyloid retention with 11C-Pittsburgh compound B (PiB) PET. We investigated the diagnostic significance of equivocal PiB PET findings.

Methods

This retrospective study included 101 consecutive patients complaining of cognitive disorders (30 Alzheimer’s disease, 25 mild cognitive impairment, 8 Lewy body disease, 7 frontotemporal lobar degeneration, 31 others) who underwent both 11C-PiB PET and 18F-fluorodeoxy-d-glucose (FDG) PET. We visually classified PiB-positive, PiB-equivocal or PiB-negative ratings according to cortical uptake. For quantitative assessments of PiB PET, standard uptake values referred to cerebellar cortex (SUVR) were calculated in regional template volume of interests (frontal, temporoparietal, precuneus/posterior cingulate cortex, cerebral white matter and cerebellar cortex). The results of visual assessment were compared with the regional and mean cortical SUVRs and cortical-to-white matter ratio of PiB uptake, as well as clinical and FDG PET findings.

Results

Among the 101 scans, 41 were PiB negative, 11 were PiB equivocal, and 49 were rated PiB positive in the visual assessments. The mean cortical SUVR and cortical-to-white matter ratio were 0.97 ± 0.07 and 0.57 ± 0.21 in PiB-negative, 1.51 ± 0.17 and 0.75 ± 0.06 in PiB equivocal and 2.10 ± 0.33 and 0.97 ± 0.11 in PiB-positive group, respectively. Nine of 11 subjects with PiB-equivocal findings had cognitive impairments and FDG distribution compatible with Alzheimer’s disease or dementia with Lewy bodies.

Conclusions

We considered equivocal visual findings on PiB PET equivalent to PiB-positive with slight cortical uptake. In addition, slight cortical amyloid deposits were considered to cause cerebral metabolic abnormality and cognitive impairment. Although mean cortical SUVR was more sensitive than visual assessment because of low cortical-to-white matter contrast due to non-specific accumulation in white matter, it is important not to overlook small amounts of cortical uptake of PiB in visual inspection for exact diagnosis.
Literatur
1.
Zurück zum Zitat Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburg compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburg compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed
2.
Zurück zum Zitat Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32:S20–36.CrossRefPubMedCentralPubMed Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32:S20–36.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko S, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound B. J Cereb Blood Flow Metabol. 2005;25:1528–47.CrossRef Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko S, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound B. J Cereb Blood Flow Metabol. 2005;25:1528–47.CrossRef
4.
Zurück zum Zitat Yaqub M, Tolboom N, Boellaard R, van Berckel BNM, van Triburg EW, Luurtsema G, et al. Simplified parametric methods for [11C] PIB studies. Neuroimage. 2008;42:76–86.CrossRefPubMed Yaqub M, Tolboom N, Boellaard R, van Berckel BNM, van Triburg EW, Luurtsema G, et al. Simplified parametric methods for [11C] PIB studies. Neuroimage. 2008;42:76–86.CrossRefPubMed
5.
Zurück zum Zitat Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantitation of Pittsburgh compound B amyloid imaging PET studies: a comparable analysis. J Nucl Med. 2005;46:1959–72.PubMed Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantitation of Pittsburgh compound B amyloid imaging PET studies: a comparable analysis. J Nucl Med. 2005;46:1959–72.PubMed
6.
Zurück zum Zitat Van Berckel BNM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodological consideration. J Nucl Med. 2013;54:1570–6.CrossRefPubMed Van Berckel BNM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodological consideration. J Nucl Med. 2013;54:1570–6.CrossRefPubMed
7.
Zurück zum Zitat McKhann G, Drachman D, Foistein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer’s disease-report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939.CrossRefPubMed McKhann G, Drachman D, Foistein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer’s disease-report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939.CrossRefPubMed
8.
Zurück zum Zitat McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology. 2005;65:1863–72.CrossRefPubMed McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology. 2005;65:1863–72.CrossRefPubMed
9.
Zurück zum Zitat Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.CrossRefPubMed Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.CrossRefPubMed
10.
Zurück zum Zitat Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration—a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.CrossRefPubMed Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration—a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.CrossRefPubMed
11.
Zurück zum Zitat Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.CrossRefPubMed Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.CrossRefPubMed
12.
Zurück zum Zitat Federo-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198–204.CrossRef Federo-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198–204.CrossRef
13.
Zurück zum Zitat Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.CrossRefPubMed Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.CrossRefPubMed
14.
Zurück zum Zitat Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies; metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol. 2002;15:200–9.CrossRefPubMed Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies; metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol. 2002;15:200–9.CrossRefPubMed
15.
Zurück zum Zitat Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45.CrossRefPubMedCentralPubMed Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.CrossRefPubMed Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.CrossRefPubMed
17.
Zurück zum Zitat Suotunen T, Hirvonen J, Immonen-Raiha P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of [11C]-PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1141–7.CrossRefPubMed Suotunen T, Hirvonen J, Immonen-Raiha P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of [11C]-PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1141–7.CrossRefPubMed
18.
Zurück zum Zitat Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152–60.CrossRefPubMedCentralPubMed Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152–60.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207–15.CrossRefPubMedCentralPubMed Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207–15.CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed
21.
Zurück zum Zitat Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, et al. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:209–19.CrossRefPubMedCentralPubMed Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, et al. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:209–19.CrossRefPubMedCentralPubMed
Metadaten
Titel
Investigation of 11C-PiB equivocal PET findings
verfasst von
Chisa Hosokawa
Kazunari Ishii
Tomoko Hyodo
Kenta Sakaguchi
Kimio Usami
Kenji Shimamoto
Yuzuru Yamazoe
Makoto Hosono
Kazushi Hanada
Masami Ueda
Kazuma Saigo
Takamichi Murakami
Publikationsdatum
01.02.2015
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 2/2015
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-014-0924-8

Weitere Artikel der Ausgabe 2/2015

Annals of Nuclear Medicine 2/2015 Zur Ausgabe

Acknowledgements to Reviewers

Acknowledgements to Reviewers